$GILD News Why Apple exemplifies everything th
Post# of 89407
Posted On: 09/10/2014 1:03:57 PM
$GILD News
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Surviving "a complex time in the market" 4:57 a.m. Aug. 25, 2014 - MarketWatch
10 S&P 500 companies growing faster than their rivals 3:29 a.m. Aug. 20, 2014 - Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt
Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary 12:00 p.m. Today - Zacks.com
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog 11:17 a.m. Today - Zacks.com
ERBA Diagnostics (ERB) in Focus: Stock Up 7% - Tale of the Tape 9:39 a.m. Today - Zacks.com
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog 9:00 a.m. Today - Zacks.com
Stemline Therapeutics (STML) in Focus: Stock Up 12.3% - Tale of the Tape 8:51 a.m. Today - Zacks.com
AstraZeneca Presents Unfavorable Benralizumab Study Data - Analyst Blog 6:35 p.m. Sept. 9, 2014 - Zacks.com
Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog 6:20 p.m. Sept. 9, 2014 - Zacks.com
Gilead Sciences' (GILD) CEO Presents at Morgan Stanley Healthcare Conference (Transcript) 4:56 p.m. Sept. 9, 2014 - Seeking Alpha
Gilead Sciences (GILD) Presents at Morgan Stanley Global Healthcare Conference (Transcript) 4:56 p.m. Sept. 9, 2014 - Seeking Alpha
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog 4:50 p.m. Sept. 9, 2014 - Zacks.com
Hospira Down on Legal Blow; Court Allows Generic Precedex - Analyst Blog 4:45 p.m. Sept. 9, 2014 - Zacks.com
Bayer Presents Positive Long-Term Results on Adempas - Analyst Blog 4:25 p.m. Sept. 9, 2014 - Zacks.com
2 Years Of Dividend Growth Investing - 10 Lessons I Have Learned 2:33 p.m. Sept. 9, 2014 - Seeking Alpha
AbbVie Is Betting Big On Infinity Pharmaceuticals But Should You? 12:59 p.m. Sept. 9, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: GE, F, GILD 9:59 a.m. Sept. 9, 2014 - TheStreet.com
Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015 7:44 a.m. Sept. 9, 2014 - 247WallSt.com
Achillion - An Options Strategy For A Potential Acquisition 6:07 p.m. Sept. 8, 2014 - Seeking Alpha
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog 6:05 p.m. Sept. 8, 2014 - Zacks.com
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog 6:00 p.m. Sept. 8, 2014 - Zacks.com
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog 5:35 p.m. Sept. 8, 2014 - Zacks.com
Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 9:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher 9:20 a.m. Sept. 4, 2014 - PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences in September 5:00 p.m. Sept. 3, 2014 - BusinessWire - BZX
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay 9:05 a.m. Sept. 3, 2014 - PR Newswire - PRF
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard 9:10 a.m. Aug. 27, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver 9:31 a.m. Aug. 21, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Surviving "a complex time in the market" 4:57 a.m. Aug. 25, 2014 - MarketWatch
10 S&P 500 companies growing faster than their rivals 3:29 a.m. Aug. 20, 2014 - Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang
Biogen results crush consensus 4:55 p.m. July 23, 2014 - The Trading Deck
Gilead trounces estimates on strong Sovaldi sales 4:19 p.m. July 23, 2014 - MarketWatch.com
Gilead trounces estimates for earnings, sales, Sovaldi 4:17 p.m. July 23, 2014 - Russ Britt
Biotech ETFs Slip on Gilead Weakness; Buying Opportunity Now? - ETF News And Commentary 12:00 p.m. Today - Zacks.com
Biotech Stock Roundup: AbbVie Ties Up with Infinity, Keryx Slips on FDA Approval - Analyst Blog 11:17 a.m. Today - Zacks.com
ERBA Diagnostics (ERB) in Focus: Stock Up 7% - Tale of the Tape 9:39 a.m. Today - Zacks.com
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog 9:00 a.m. Today - Zacks.com
Stemline Therapeutics (STML) in Focus: Stock Up 12.3% - Tale of the Tape 8:51 a.m. Today - Zacks.com
AstraZeneca Presents Unfavorable Benralizumab Study Data - Analyst Blog 6:35 p.m. Sept. 9, 2014 - Zacks.com
Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog 6:20 p.m. Sept. 9, 2014 - Zacks.com
Gilead Sciences' (GILD) CEO Presents at Morgan Stanley Healthcare Conference (Transcript) 4:56 p.m. Sept. 9, 2014 - Seeking Alpha
Gilead Sciences (GILD) Presents at Morgan Stanley Global Healthcare Conference (Transcript) 4:56 p.m. Sept. 9, 2014 - Seeking Alpha
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog 4:50 p.m. Sept. 9, 2014 - Zacks.com
Hospira Down on Legal Blow; Court Allows Generic Precedex - Analyst Blog 4:45 p.m. Sept. 9, 2014 - Zacks.com
Bayer Presents Positive Long-Term Results on Adempas - Analyst Blog 4:25 p.m. Sept. 9, 2014 - Zacks.com
2 Years Of Dividend Growth Investing - 10 Lessons I Have Learned 2:33 p.m. Sept. 9, 2014 - Seeking Alpha
AbbVie Is Betting Big On Infinity Pharmaceuticals But Should You? 12:59 p.m. Sept. 9, 2014 - Seeking Alpha
3 Stocks Reiterated As A Buy: GE, F, GILD 9:59 a.m. Sept. 9, 2014 - TheStreet.com
Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015 7:44 a.m. Sept. 9, 2014 - 247WallSt.com
Achillion - An Options Strategy For A Potential Acquisition 6:07 p.m. Sept. 8, 2014 - Seeking Alpha
Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog 6:05 p.m. Sept. 8, 2014 - Zacks.com
OncoMed's Shares Gain on Lifting of Partial Clinical Hold - Analyst Blog 6:00 p.m. Sept. 8, 2014 - Zacks.com
Prana Biotechnology Up on Orphan Drug Status for PBT2 - Analyst Blog 5:35 p.m. Sept. 8, 2014 - Zacks.com
Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 9:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher 9:20 a.m. Sept. 4, 2014 - PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences in September 5:00 p.m. Sept. 3, 2014 - BusinessWire - BZX
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay 9:05 a.m. Sept. 3, 2014 - PR Newswire - PRF
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard 9:10 a.m. Aug. 27, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver 9:31 a.m. Aug. 21, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX
U.S. Food and Drug Administration Approves Gilead’s Zydelig® (idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 11:49 a.m. July 23, 2014 - BusinessWire - BZX
Gilead Sciences to Release Second Quarter 2014 Financial Results on Wednesday, July 23, 2014 5:00 p.m. July 16, 2014 - BusinessWire - BZX
Critical Alerts For SunEdison, Twitter, Gilead Sciences, Darden Restaurants, and Blackrock Released By InvestorsObserver 9:31 a.m. July 14, 2014 - PR Newswire - PRF
(0)
(0)